Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Bayer Will Acquire Novartis Facility
April 2, 2007
| A version of this story appeared in
Volume 85, Issue 14
Bayer Schering Pharma will acquire Novartis' biologics facility in Emeryville, Calif., for $200 million. Novartis currently uses the facility to supply Bayer with interferon beta 1-b for Bayer's multiple sclerosis drug Betaseron. As part of the deal, Bayer will license rights to the drug to Novartis, which plans to launch its own branded version in 2009. Bayer will continue to pay royalties to Novartis until October 2008, when the companies' original regulatory filing expires, and will supply interferon beta 1-b to Novartis upon approval of the Swiss firm's version of the drug.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter